Microtransplantation in Older Patients With Acute Myeloid Leukemia

International Multi-center Clinical Study on Microtransplantation for Treatment of Newly Diagnosed Elderly Acute Myeloid Leukemia (EAML)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02831192

Enrollment

150

Registered

2016-07-13

Start date

2006-05-31

Completion date

2015-07-31

Last updated

2016-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

The purpose of this study is to see whether HLA-mismatched donor cells infusion with chemotherapy (microtransplantation，MST) could increase complete remission (CR) and improve survival in older patients with acute myeloid leukemia (AML)，the investigators conducted a prospective, multicenter clinical trial of HLA-mismatched MST to estimate outcomes and toxicities.

Interventions

BIOLOGICALmicrotransplantation

HLA mismatched donor mobilized prepheral stem cell infusion

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

60 Years to 90 Years

Healthy volunteers

Inclusion criteria

* de novo acute myeloid leukemia * age 60-90 * have HLA mismatched donor

Exclusion criteria

* have no suitable donor or donor refused * patient refused to accept donor cells

Design outcomes

Primary

Measure	Time frame
Graft versus host disease	1 month

Secondary

Measure	Time frame
overall survival	2 years
leukemia free survival	2 years
complete remission rate	2 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026